5th mRNA Process Development and CMC Summit

Memo

mRNA vaccines and therapeutics remain one of the most promising modalities to transform the treatment of disease indications. However, challenges associated with accurate CMC remain a critical bottleneck, preventing new therapeutics from reaching the market. Enter the 5th mRNA Process Development and CMC Summit, a 2-day, multi-track, industry-leading conference uniting biopharma's C-level decision-makers and strategic experts with leading CDMOs, manufacturers, sequencers, and key stakeholders. Together, they share one common goal: define the blueprint for process development strategies that will enable pure, scalable mRNA therapeutics to reach patients through commercially viable solutions. Join 150+ global experts across process development, analytical, formulation, delivery, and CMC, bringing forward new data and strategies that are shaping the next wave of mRNA development - from circular and self-amplifying RNA, to cutting-edge cell and gene editing applications. URLs:Tickets: https://go.evvnt.com/3664030-2?pid=5569Brochure: https://go.evvnt.com/3664030-3?pid=5569 Date and Time: Wednesday, 30 September 2026 at 08:00 - Thursday, 01 October 2026 at 18:00 Venue details: Wyndham Boston Beacon Hill, 5 Blossom Street, Boston, Massachusetts, 02114, United States Category: Conferences | Science, Health and Medicine | Pharmaceuticals Prices:Biopharma: USD 0.00,Service Provider Pricing: USD 3699.00 Speakers: Zhinan Xia, Chief Scientific Officer, AbImmune Therapeutics, Daryl Drummond, Chief Scientific Officer, Akagera Medicines, Peter Weinstein, Chief Executive Officer, Circurna, Vaishali Shukla, Vice President, CGT and API Global Expansion, Eli Lilly and Co., T.J. Craddick, Chief Scientific Officer, HuidaGene Therapeutics, Joshua McGee, Chief Scientific Officer and Co-Founder, Keylicon Biosciences, Jeffrey Ulmer, President C-Suite, TechImmune, Anubhav Arora, Director, Discovery CMC, Apellis Pharmaceuticals, Junta Shimada, Researcher, Downstream Processing CMC, Astellas, Zimeng Wang, Associate Principal Scientist, AstraZeneca, Shirisha Meda, Associate Director Medical and Health, BioNTech, Atsuko Sakurai-Sangria, Director, CMC, Centivax, Joshua Farb, Founder and Principal Consulting, CMC Process Development, Farb Consulting, Kamalakar Chatla, Technical Development Principal Scientist, Genentech, Jack Chu, Principal Scientist, GSK, Jennifer Lin, Director, Early Development and In Process Analytics, GSK, Amit Khandhar, Director of Formulations, HDT Bio, Taesun Eom, Director, RNA Technologies, nChroma Bio, Sandeep Kongara, Associate Director - External Manufacturing, Precision BioSciences, Ryan Phillips, Associate Director, Head of Supply Chain and Strategic Sourcing, Precision BioSciences, Joseph Elich, Director, Process Development and CMC, Prime Medicine, Líliam Oliveira, Director of Formulation and Process Development, Providence Therapeutics, Ching Kim Tye, Head of DP Platform and Early Clinical Development, Sanofi, Aidan Cola, Principal Associate Scientist, mRNA Process Development, Strand Therapeutics, Yingzhong Li, President and Chief Executive Officer, SunVax mRNA Therapeutics, Mohit Gupta, Principal Scientist, Tessera Therapeutics, Gautam Sanyal, Principal Consultant, Vaccine Analytics, Cangjie Yang, Associate Director, Zipcode Bio